NGN Capital

Portfolio · 3

Phytolon

Production of Natural Food Colorants

1 round $23.6M committed Latest: 2026-05

Cardiovalve

Cardiovascular Replacement Devices for Minimally Invasive Surgery

1 round $40.0M committed Latest: 2020-08

Valtech Cardio

Mitral Valve Repair Implants

1 round $17.8M committed Latest: 2010-03

Investment activity

2 portfolio exits on record.

Q&A

What is NGN Capital's most recent exit?

NGN Capital's most recent exit was Cardiovalve, which was acquired by Venus Medtech in March 2022 for $150M.

What is NGN Capital's sector focus?

NGN Capital primarily focuses on the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name some of NGN Capital's notable portfolio companies?

NGN Capital's notable portfolio companies include Cardiovalve and Valtech Cardio, both of which have been acquired.

What was NGN Capital's first recorded exit?

NGN Capital's first recorded exit was Valtech Cardio, which was acquired by Edwards Lifesciences in January 2017 for $340M.

What is the typical investment range for NGN Capital?

NGN Capital's investment range is between $17.8M and $40M.

How many exits has NGN Capital had in the last five years?

NGN Capital has had one exit in the last five years, with Cardiovalve being acquired in March 2022.